In the fourth quarter, we continued to face headwinds to our pharmacy margin from ongoing pressure from reimbursement and generic drug inflation. To address the pressure on our pharmacy margin, we are focused on our contracting strategy to a lot of our payer contracts to the realities of an inflationary versus a deflationary market. We are also aggressively working to reduce total pharmacy costs by increasing efficiencies and providing high quality and cost effective pharmacy services.
Th
